ArticleMolecular cancer therapeutics2021
Targeted Therapy to β3 Integrin Reduces Chemoresistance in Breast Cancer Bone Metastases.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 22 citations in OpenAlex.
- Decoding triple negative breast cancer bone metastasis: from 3D bioprinted models to clinical translation.Journal of nanobiotechnology · 2026Review
- Gemcitabine-induced β4 integrin drives cancer progression and gemcitabine resistance in pancreatic cancer.Journal of experimental & clinical cancer research : CR · 2026Article
- Integrins in Cancer Drug Resistance: Molecular Mechanisms and Clinical Implications.International journal of molecular sciences · 2025Review
- Nanotheranostics in Breast Cancer Bone Metastasis: Advanced Research Progress and Future Perspectives.Pharmaceutics · 2024Review
- Bone targeted nano-drug and nano-delivery.Bone research · 2024Review
- The Role of αvβ3 Integrin in Cancer Therapy Resistance.Biomedicines · 2024Review
- Integrin αvβ3 Upregulation in Response to Nutrient Stress Promotes Lung Cancer Cell Metabolic Plasticity.Cancer research · 2024Article
- ID4-dependent secretion of VEGFA enhances the invasion capability of breast cancer cells and activates YAP/TAZ via integrin β3-VEGFR2 interaction.Cell death & disease · 2024Article
- Upregulation of fibronectin and its integrin receptors - an adaptation to isolation stress that facilitates tumor initiation.Journal of cell science · 2023Article
- p38MAPKα Stromal Reprogramming Sensitizes Metastatic Breast Cancer to Immunotherapy.Cancer discovery · 2023Article
- The role of integrin family in bone metabolism and tumor bone metastasis.Cell death discovery · 2023Review
- Integrin αvβ3 Is a Master Regulator of Resistance to TKI-Induced Ferroptosis in HER2-Positive Breast Cancer.Cancers · 2023Article
- Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers.Frontiers in endocrinology · 2023Review
- Muscle and Bone Defects in Metastatic Disease.Current osteoporosis reports · 2022Review
- Clinical Effect of Laparoscopic Radical Surgery Combined with Neoadjuvant Chemotherapy in Treating Cervical Cancer and Its Influence on Postoperative Complications and Adverse Reaction Rates.Journal of healthcare engineering · 2022Article
- Mechanisms of Cell Adhesion Molecules in Endocrine-Related Cancers: A Concise Outlook.Frontiers in endocrinology · 2022Review
- Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy.International journal of molecular sciences · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 2 institutions in 1 country.
Gregory C FoxDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Xinming SuDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Jennifer L DavisDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-1060-3855
Yalin XuDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Kristin A KwakwaDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Michael H RossDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Francesca FontanaDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Jingyu XiangDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Alison K EsserDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Elizabeth CordellDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Kristen PagliaiDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Ha X DangDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Jothilingam SivapackiamMallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri.
Sheila A StewartSiteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri.
Christopher A MaherDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
Suzanne J BakewellDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri.
James A J FitzpatrickDepartment of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri.
Vijay SharmaMallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri.
Samuel AchilefuSiteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-3133-6717
Deborah J VeisDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Gregory M LanzaDepartment of Medicine, Division of Cardiology, Washington University School of Medicine, St. Louis, Missouri.
Katherine N WeilbaecherDepartment of Medicine, Division of Molecular Oncology, Washington University School of Medicine, St. Louis, Missouri. kweilbae@wustl.edu.ORCID 0000-0002-7137-4742
Washington University in St. Louis · USJames S. McDonnell Foundation · US
Funding
Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0MWU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8MNATIONAL RESEARCH SERVICE AWARD-MEDICAL SCIENTISTT32GM007200 · NIGMS · WASHINGTON UNIVERSITY · PI YOKOYAMA, WAYNE M. · 1985 to 2024
$59.8MRole of Inflammation in Tax-mediated TumorigenesisP01CA100730 · NCI · WASHINGTON UNIVERSITY · PI Lee Ratner · 2003 to 2026
$44.8MTraining/DisseminationP41EB025815 · NIBIB · WASHINGTON UNIVERSITY · PI Buck E. Rogers · 2018 to 2026
$12.7MProject 2 - Radiation-Induced Treatment of Multiple Myeloma using NanoparticlesU54CA199092 · NCI · WASHINGTON UNIVERSITY · PI ACHILEFU, SAMUEL · 2015 to 2019
$11.5MTUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gay M Crooks, David A. Nathanson · 1985 to 2026
$10.5MResource Based Center for Musculoskeletal Biology and Medicine (Overall Application)P30AR074992 · NIAMS · WASHINGTON UNIVERSITY · PI MATTHEW J SILVA · 2019 to 2026
$6.8MThe Role of the Osteoblast Secretome in Bone FormationP30AR057235 · NIAMS · WASHINGTON UNIVERSITY · PI SILVA, MATTHEW J · 2009 to 2018
$5.7MMOLECULAR ONCOLOGY TRAINING GRANTT32CA113275 · NCI · WASHINGTON UNIVERSITY · PI Matthew J Walter · 2006 to 2026
$5.7MSkeletal Disorders Training ProgramT32AR060719 · NIAMS · WASHINGTON UNIVERSITY · PI Roberto Civitelli · 2011 to 2026
$4.6MOVERCOMING THE PROTECTIVE BARRIERS OF BREAST CANCER IN BONE MARROW WITH TARGETED PRODRUG NANOTHERAPYR01CA216840 · NCI · WASHINGTON UNIVERSITY · PI LANZA, GREGORY M, WEILBAECHER, KATHERINE NELSON · 2018 to 2022
$3.1MNCATS NIH HHS UL1 TR002345NCI NIH HHS P01 CA100730NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA154737NCI NIH HHS R01 CA216840NCI NIH HHS T32 CA009056NCI NIH HHS T32 CA113275NCI NIH HHS U54 CA199092NCRR NIH HHS S10 RR027552NHLBI NIH HHS R01 HL111163NHLBI NIH HHS R01 HL142297NIAMS NIH HHS P30 AR057235NIAMS NIH HHS P30 AR074992NIAMS NIH HHS R01 AR070030NIAMS NIH HHS R21 AR073507NIAMS NIH HHS T32 AR060719NIBIB NIH HHS P41 EB025815NIGMS NIH HHS T32 GM007200NIH HHS S10 OD021694
Abstract
Breast cancer bone metastases are common and incurable. Tumoral integrin β3 (β3) expression is induced through interaction with the bone microenvironment. Although β3 is known to promote bone colonization, its functional role during therapy of established bone metastases is not known. We found increased numbers of β3
Indexed as
AnimalsAntineoplastic AgentsBone NeoplasmsBreast NeoplasmsCell Line, TumorDocetaxelDrug Resistance, NeoplasmFemaleHumansIntegrin beta3MiceMice, Inbred C57BLMolecular Targeted TherapySurvival AnalysisAntineoplastic AgentsDocetaxelIntegrin beta3
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.